For the time being, the go-to treatment for either lymphoma and leukemia in dogs is chemotherapy. However, very few dogs get actually cured and most of them will relapse sooner or later.
The Ohio State University Veterinary Medical Center is currently enrolling dogs in a novel therapy clinical trial.
This therapy uses a compound that inhibits PI3 kinase (PI3K), an enzyme involved in cell signaling. This comes in several isoforms (different forms of the same protein), each of which has a different role in different types of cells.
One of these is particularly important for tumor growth in lymphoma and leukemia.
TV1001, the compound tested in this study, should selectively inhibit this enzyme, inducing death of the cancer cells/apoptosis.
Dogs newly diagnosed with lymphoma or leukemia, and those with relapsed disease are eligible for this trial.
Clinical Trials for Pets at the OSU Veterinary Medical Center
A Phase I dose escalation study evaluating the safety and efficacy of RV1001, an isoform selective PI3K inhibitor, in dogs with lymphoma